Medicilon(SH:688202)2024-02-02 10:10Group 1: Financial Performance - The net profit attributable to shareholders for 2023 decreased compared to the same period last year, primarily due to a significant decline in market demand and increased competition in the pharmaceutical industry, leading to an estimated revenue drop of around 15% [3] - Operating expenses and fixed asset depreciation increased as the company gradually invested in new R&D laboratories, along with a notable rise in labor costs and related expenses compared to 2022 [3] - The decline in the price of laboratory animals at the end of the reporting period led to the company prudently recognizing inventory impairment, negatively impacting operating profit [3] Group 2: Supply Chain and Pricing - The price of laboratory monkeys has recently decreased, prompting the company to actively diversify procurement channels and deepen cooperation with suppliers to ensure stable supply [4] Group 3: Share Buyback Progress - As of January 31, 2024, the company has repurchased a total of 488,426 shares through centralized bidding, accounting for 0.3627% of the total share capital, with a total expenditure of RMB 29,952,362.56 [4]